- Home
- CHRS vs PYXS Comparison
CHRS vs PYXS Comparison
Compare CHRS & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- PYXS
- Stock Information
- Founded
- CHRS 2010
- PYXS 2018
- Country
- CHRS United States
- PYXS United States
- Employees
- CHRS N/A
- PYXS N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- PYXS Health Care
- Exchange
- CHRS Nasdaq
- PYXS Nasdaq
- Market Cap
- CHRS 84.2M
- PYXS 75.0M
- IPO Year
- CHRS 2014
- PYXS 2021
- Fundamental
- Price
- CHRS $0.76
- PYXS $1.08
- Analyst Decision
- CHRS Buy
- PYXS Strong Buy
- Analyst Count
- CHRS 3
- PYXS 5
- Target Price
- CHRS $4.68
- PYXS $9.00
- AVG Volume (30 Days)
- CHRS 1.3M
- PYXS 723.4K
- Earning Date
- CHRS 08-07-2025
- PYXS 08-13-2025
- Dividend Yield
- CHRS N/A
- PYXS N/A
- EPS Growth
- CHRS N/A
- PYXS N/A
- EPS
- CHRS N/A
- PYXS N/A
- Revenue
- CHRS $272,251,000.00
- PYXS N/A
- Revenue This Year
- CHRS N/A
- PYXS N/A
- Revenue Next Year
- CHRS $106.56
- PYXS N/A
- P/E Ratio
- CHRS N/A
- PYXS N/A
- Revenue Growth
- CHRS 19.87
- PYXS N/A
- 52 Week Low
- CHRS $0.66
- PYXS $0.83
- 52 Week High
- CHRS $2.43
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- CHRS 46.35
- PYXS 39.82
- Support Level
- CHRS $0.72
- PYXS $1.14
- Resistance Level
- CHRS $0.77
- PYXS $1.32
- Average True Range (ATR)
- CHRS 0.04
- PYXS 0.07
- MACD
- CHRS 0.00
- PYXS -0.02
- Stochastic Oscillator
- CHRS 38.69
- PYXS 3.33
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.